Key Points

  • VWF gene variants that modify FVIII binding influence FVIII PK.

  • Variants in clearance receptors for VWF-FVIII influence FVIII PK.

Abstract

Factor VIII (FVIII) pharmacokinetic (PK) properties show high interpatient variability in hemophilia A patients. Although previous studies have determined that age, body mass index, von Willebrand factor antigen (VWF:Ag) levels, and ABO blood group status can influence FVIII PK, they do not account for all observed variability. In this study, we aim to describe the genetic determinants that modify the FVIII PK profile in a population of 43 pediatric hemophilia A patients. We observed that VWF:Ag and VWF propeptide (VWFpp)/VWF:Ag, but not VWFpp, were associated with FVIII half-life. VWFpp/VWF:Ag negatively correlated with FVIII half-life in patients with non-O blood type, but no correlation was observed for type O patients, suggesting that von Willebrand factor (VWF) half-life, as modified by the ABO blood group, is a strong regulator of FVIII PK. The FVIII-binding activity of VWF positively correlated with FVIII half-life, and the rare or low-frequency nonsynonymous VWF variants p.(Arg826Lys) and p.(Arg852Glu) were identified in patients with reduced VWF:FVIIIB but not VWF:Ag. Common variants at the VWF, CLEC4M, and STAB2 loci, which have been previously associated with plasma levels of VWF and FVIII, were associated with the FVIII PK profile. Together, these studies characterize the mechanistic basis by which VWF clearance and ABO glycosylation modify FVIII PK in a pediatric population. Moreover, this study is the first to identify non-VWF and non-ABO variants that modify FVIII PK in pediatric hemophilia A patients.

REFERENCES

REFERENCES
1.
Fischer
K
,
Pendu
R
,
van Schooten
CJ
, et al
.
Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients
.
PLoS One
.
2009
;
4
(
8
):
e6745
.
2.
Björkman
S
,
Folkesson
A
,
Berntorp
E
.
In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting
.
Haemophilia
.
2007
;
13
(
1
):
2
-
8
.
3.
Collins
PW
,
Björkman
S
,
Fischer
K
, et al
.
Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens
.
J Thromb Haemost
.
2010
;
8
(
2
):
269
-
275
.
4.
Björkman
S
,
Blanchette
VS
,
Fischer
K
, et al;
Advate Clinical Program Group
.
Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring
.
J Thromb Haemost
.
2010
;
8
(
4
):
730
-
736
.
5.
Hazendonk
HCAM
,
van Moort
I
,
Mathôt
RAA
, et al;
OPTI-CLOT study group
.
Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?
Blood Rev
.
2018
;
32
(
4
):
265
-
271
.
6.
Koedam
JA
,
Meijers
JC
,
Sixma
JJ
,
Bouma
BN
.
Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor
.
J Clin Invest
.
1988
;
82
(
4
):
1236
-
1243
.
7.
Kaufman
RJ
,
Dorner
AJ
,
Fass
DN
.
von Willebrand factor elevates plasma factor VIII without induction of factor VIII messenger RNA in the liver
.
Blood
.
1999
;
93
(
1
):
193
-
197
.
8.
Weiss
HJ
,
Sussman
II
,
Hoyer
LW
.
Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand’s disease
.
J Clin Invest
.
1977
;
60
(
2
):
390
-
404
.
9.
Tuddenham
EG
,
Lane
RS
,
Rotblat
F
, et al
.
Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand’s disease
.
Br J Haematol
.
1982
;
52
(
2
):
259
-
267
.
10.
Morfini
M
,
Mannucci
PM
,
Tenconi
PM
, et al
.
Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease
.
Thromb Haemost
.
1993
;
70
(
2
):
270
-
272
.
11.
Song
J
,
Chen
F
,
Campos
M
, et al
.
Quantitative influence of ABO blood groups on factor VIII and its ratio to von Willebrand factor, novel observations from an ARIC study of 11,673 subjects
.
PLoS One
.
2015
;
10
(
8
):
e0132626
.
12.
Gill
JC
,
Endres-Brooks
J
,
Bauer
PJ
,
Marks
WJ
Jr
,
Montgomery
RR
.
The effect of ABO blood group on the diagnosis of von Willebrand disease
.
Blood
.
1987
;
69
(
6
):
1691
-
1695
.
13.
Kepa
S
,
Horvath
B
,
Reitter-Pfoertner
S
, et al
.
Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A
.
Haemophilia
.
2015
;
21
(
3
):
343
-
350
.
14.
Fijnvandraat
K
,
Peters
M
,
ten Cate
JW
.
Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels
.
Br J Haematol
.
1995
;
91
(
2
):
474
-
476
.
15.
Huffman
JE
,
de Vries
PS
,
Morrison
AC
, et al
.
Rare and low-frequency variants and their association with plasma levels of fibrinogen, FVII, FVIII, and vWF
.
Blood
.
2015
;
126
(
11
):
e19
-
e29
.
16.
Smith
NL
,
Chen
M-H
,
Dehghan
A
, et al;
Wellcome Trust Case Control Consortium
.
Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium
.
Circulation
.
2010
;
121
(
12
):
1382
-
1392
.
17.
Casonato
A
,
Galletta
E
,
Sarolo
L
,
Daidone
V
.
Type 2N von Willebrand disease: characterization and diagnostic difficulties
.
Haemophilia
.
2018
;
24
(
1
):
134
-
140
.
18.
Swystun
LL
,
Georgescu
I
,
Mewburn
J
, et al
.
Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice
.
J Thromb Haemost
.
2017
;
15
(
8
):
1607
-
1619
.
19.
Mufti
AH
,
Ogiwara
K
,
Swystun
LL
, et al;
European Group on von Willebrand disease (EU-VWD) and Zimmerman Program for the Molecular and Clinical Biology of von Willebrand disease (ZPMCB-VWD) Study Groups
.
The common VWF single nucleotide variants c.2365A>G and c.2385T>C modify VWF biosynthesis and clearance
.
Blood Adv
.
2018
;
2
(
13
):
1585
-
1594
.
20.
Morange
PE
,
Tregouet
DA
,
Frere
C
, et al
.
Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort
.
Br J Haematol
.
2005
;
128
(
1
):
91
-
99
.
21.
Gallinaro
L
,
Cattini
MG
,
Sztukowska
M
, et al
.
A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor
.
Blood
.
2008
;
111
(
7
):
3540
-
3545
.
22.
Sabater-Lleal
M
,
Huffman
JE
,
de Vries
PS
, et al
.
Genome-wide association transethnic meta-analyses identifies novel associations regulating coagulation factor VIII and von Willebrand factor plasma levels
.
Circulation
.
2019
;
139
(
5
):
620
-
635
.
23.
Swystun
LL
,
Lai
JD
,
Notley
C
, et al
.
The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity
.
J Clin Invest
.
2018
;
128
(
9
):
4057
-
4073
.
24.
Rydz
N
,
Swystun
LL
,
Notley
C
, et al
.
The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels
.
Blood
.
2013
;
121
(
26
):
5228
-
5237
.
25.
Swystun
LL
,
Ogiwara
K
,
Lai
JD
, et al
.
The scavenger receptor SCARA5 is an endocytic receptor for von Willebrand factor expressed by littoral cells in the human spleen
.
J Thromb Haemost
.
2019
;
17
(
8
):
1384
-
1396
.
26.
Albánez
S
,
Ogiwara
K
,
Michels
A
, et al
.
Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms
.
J Thromb Haemost
.
2016
;
14
(
5
):
953
-
963
.
27.
Haberichter
SL
,
Balistreri
M
,
Christopherson
P
, et al
.
Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival
.
Blood
.
2006
;
108
(
10
):
3344
-
3351
.
28.
Morfini
M
,
Lee
M
,
Messori
A
;
Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis
.
The design and analysis of half-life and recovery studies for factor VIII and factor IX
.
Thromb Haemost
.
1991
;
66
(
3
):
384
-
386
.
29.
Lee
M
,
Morfini
M
,
Negrier
C
,
Chamouard
V
.
The pharmacokinetics of coagulation factors
.
Haemophilia
.
2006
;
12
(
suppl 3
):
1
-
7
.
30.
Björkman
S
.
Evaluation of the TCIWorks Bayesian computer program for estimation of individual pharmacokinetics of FVIII
.
Haemophilia
.
2011
;
17
(
1
):
e239
-
e240
.
31.
Casonato
A
,
Pontara
E
,
Zerbinati
P
,
Zucchetto
A
,
Girolami
A
.
The evaluation of factor VIII binding activity of von Willebrand factor by means of an ELISA method: significance and practical implications
.
Am J Clin Pathol
.
1998
;
109
(
3
):
347
-
352
.
32.
James
PD
,
Notley
C
,
Hegadorn
C
, et al
.
The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study
.
Blood
.
2007
;
109
(
1
):
145
-
154
.
33.
Liu
H
,
Zhu
T
.
Determination of DC-SIGN and DC-SIGNR repeat region variations
.
Methods Mol Biol
.
2005
;
304
:
471
-
481
.
34.
van Dijk
K
,
van der Bom
JG
,
Lenting
PJ
, et al
.
Factor VIII half-life and clinical phenotype of severe hemophilia A
.
Haematologica
.
2005
;
90
(
4
):
494
-
498
.
35.
Canis
K
,
McKinnon
TAJ
,
Nowak
A
, et al
.
Mapping the N-glycome of human von Willebrand factor
.
Biochem J
.
2012
;
447
(
2
):
217
-
228
.
36.
Orstavik
KH
,
Magnus
P
,
Reisner
H
,
Berg
K
,
Graham
JB
,
Nance
W
.
Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level
.
Am J Hum Genet
.
1985
;
37
(
1
):
89
-
101
.
37.
de Lange
M
,
Snieder
H
,
Ariëns
RAS
,
Spector
TD
,
Grant
PJ
.
The genetics of haemostasis: a twin study
.
Lancet
.
2001
;
357
(
9250
):
101
-
105
.
38.
Lunghi
B
,
Bernardi
F
,
Martinelli
N
, et al
.
Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates
.
J Thromb Haemost
.
2019
;
17
(
8
):
1288
-
1296
.
39.
Wang
QY
,
Song
J
,
Gibbs
RA
,
Boerwinkle
E
,
Dong
JF
,
Yu
FL
.
Characterizing polymorphisms and allelic diversity of von Willebrand factor gene in the 1000 Genomes
.
J Thromb Haemost
.
2013
;
11
(
2
):
261
-
269
.
40.
Baran
B
,
Odnoczk
E
,
Stefanska-Windyga
E
, et al
.
Introduction of genetic methods in diagnostic process of von willebrand disease type 2N-single centre experience
.
Haemophilia
.
2013
;
19
(
suppl 2
):
66
-
67
.
41.
Repessé
Y
,
Costa
C
,
Palla
R
, et al
.
Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A
.
Haematologica
.
2019
;
104
(
8
):
e369
-
e372
.
42.
Lacquemant
C
,
Gaucher
C
,
Delorme
C
, et al
.
Association between high von Willebrand factor levels and the Thr789Ala vWF gene polymorphism but not with nephropathy in type I diabetes. The GENEDIAB Study Group and the DESIR Study Group
.
Kidney Int
.
2000
;
57
(
4
):
1437
-
1443
.
43.
Antoni
G
,
Oudot-Mellakh
T
,
Dimitromanolakis
A
, et al
.
Combined analysis of three genome-wide association studies on vWF and FVIII plasma levels
.
BMC Med Genet
.
2011
;
12
(
1
):
102
.
44.
van Loon
JE
,
Kavousi
M
,
Leebeek
FWG
, et al
.
von Willebrand factor plasma levels, genetic variations and coronary heart disease in an older population
.
J Thromb Haemost
.
2012
;
10
(
7
):
1262
-
1269
.
45.
van Schie
MC
,
de Maat
MPM
,
Isaacs
A
, et al
.
Variation in the von Willebrand factor gene is associated with von Willebrand factor levels and with the risk for cardiovascular disease
.
Blood
.
2011
;
117
(
4
):
1393
-
1399
.
46.
Campos
M
,
Sun
W
,
Yu
F
, et al
.
Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohort
.
Blood
.
2011
;
117
(
19
):
5224
-
5230
.
47.
van Schie
MC
,
van Loon
JE
,
de Maat
MPM
,
Leebeek
FWG
.
Genetic determinants of von Willebrand factor levels and activity in relation to the risk of cardiovascular disease: a review
.
J Thromb Haemost
.
2011
;
9
(
5
):
899
-
908
.
48.
Rawley
O
,
Nesbitt
K
,
Swystun
L
,
Lillicrap
D
.
Scavenger-receptor stabilin-2 is a major regulator of mouse VWF propeptide clearance
.
Blood Transfus
.
2017
;
15
(
suppl 3
):
s484
-
s485
.
49.
Desch
KC
,
Ozel
AB
,
Halvorsen
M
, et al
.
Exome sequencing in venous thromboembolic disease identifies excess mutation burden in PROS1, PROC, SERPINC1, STAB2 [abstract]
.
Blood
.
2016
;
128
(
22
).
Abstract 3794
.
50.
Desch
KC
,
Ozel
A
,
Halvorsen
M
, et al
.
Exome sequencing studies identify mutations in STAB2 as a genetic risk for venous thromboembolic disease [abstract]
.
Blood
.
2017
;
130
(
suppl 1
).
Abstract 457
.
51.
Khoo
U-S
,
Chan
KYK
,
Chan
VSF
,
Lin
CLS
.
DC-SIGN and L-SIGN: the SIGNs for infection
.
J Mol Med (Berl)
.
2008
;
86
(
8
):
861
-
874
.
52.
Swystun
LL
,
Notley
C
,
Georgescu
I
, et al
.
The endothelial lectin clearance receptor CLEC4M binds and internalizes factor VIII in a VWF-dependent and independent manner
.
J Thromb Haemost
.
2019
;
17
(
4
):
681
-
694
.
53.
Sanders
YV
,
van der Bom
JG
,
Isaacs
A
, et al;
WiN Study Group
.
CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease
.
J Thromb Haemost
.
2015
;
13
(
6
):
956
-
966
.
54.
Desch
KC
,
Ozel
AB
,
Siemieniak
D
, et al
.
Linkage analysis identifies a locus for plasma von Willebrand factor undetected by genome-wide association
.
Proc Natl Acad Sci USA
.
2013
;
110
(
2
):
588
-
593
.
55.
Bladbjerg
EM
,
de Maat
MPM
,
Christensen
K
,
Bathum
L
,
Jespersen
J
,
Hjelmborg
J
.
Genetic influence on thrombotic risk markers in the elderly–a Danish twin study
.
J Thromb Haemost
.
2006
;
4
(
3
):
599
-
607
.
56.
Souto
JC
,
Almasy
L
,
Soria
JM
, et al
.
Genome-wide linkage analysis of von Willebrand factor plasma levels: results from the GAIT project
.
Thromb Haemost
.
2003
;
89
(
3
):
468
-
474
.
57.
Swystun
LL
,
Lillicrap
D
.
Genetic regulation of plasma von Willebrand factor levels in health and disease
.
J Thromb Haemost
.
2018
;
16
(
12
):
2375
-
2390
.
58.
Yee
A
,
Gildersleeve
RD
,
Gu
S
, et al
.
A von Willebrand factor fragment containing the D’D3 domains is sufficient to stabilize coagulation factor VIII in mice
.
Blood
.
2014
;
124
(
3
):
445
-
452
.
59.
Solecka-Witulska
B
,
Lillicrap
D
,
Hough
C
,
Kannicht
C
.
A novel von Willebrand factor fragment acts as a chaperone to prolong the half-life of recombinant human FVIII (simoctocog alfa) in hemophilia A dogs and FVIII/VWF double knockout mice [abstract]
.
Blood
.
2017
;
130
(
suppl 1
).
Abstract 178
.
60.
Konkle
B
,
Shapiro
A
,
Quon
D
, et al
.
BIVV001: the first investigational factor VIII therapy to break through the VWF ceiling in hemophilia A, with potential for extended protection for one week or longer [abstract]
.
Blood
.
2018
;
132
(
suppl 1
).
Abstract 636
.
You do not currently have access to this content.